ArticleAIDS (London, England)2017
Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir.
Article in AIDS (London, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Incidence of impaired kidney function among people with HIV: a systematic review and meta-analysis.BMC nephrology · 2022Pooled it
- Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.Kidney international · 2018Guideline
- Association between tenofovir plasma trough concentrations in the early stage of administration and discontinuation of up to five years tenofovir disoproxil fumarate due to renal function-related adverse events in Japanese HIV-1 infected patients.Journal of pharmaceutical health care and sciences · 2024Article
- The changing landscape of HIV-associated kidney disease.Nature reviews. Nephrology · 2024Review
- FOXP3 full length splice variant is associated with kidney allograft tolerance.Frontiers in immunology · 2024Article
- Discontinuation of tenofovir disoproxil fumarate from initial ART regimens because of renal adverse events: An analysis of data from four multi-country clinical trials.PLOS global public health · 2024Article
- How to use COVID-19 antiviral drugs in patients with chronic kidney disease.Frontiers in pharmacology · 2023Review
- Pharmacokinetics and renal safety of tenofovir alafenamide with boosted protease inhibitors and ledipasvir/sofosbuvir.The Journal of antimicrobial chemotherapy · 2020Article
- The utility of kidney injury molecule-1 as an early biomarker of kidney injury in people living with HIV.International journal of STD & AIDS · 2020Article
- Dyslipidemia and cardiovascular disease in Vietnamese people with HIV on antiretroviral therapy.Global health & medicine · 2020Article
- The HIV protease inhibitor darunavir prevents kidney injury via HIV-independent mechanisms.Scientific reports · 2019Article
- Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study.The Journal of infectious diseases · 2019Article
- Tenofovir disoproxil fumarate initiation and changes in urinary biomarker concentrations among HIV-infected men and women.AIDS (London, England) · 2019Observational
- Cellular senescence is associated with reorganization of the microtubule cytoskeleton.Cellular and molecular life sciences : CMLS · 2019Article
- Changes in renal function with long-term exposure to antiretroviral therapy in HIV-infected adults in Asia.Pharmacoepidemiology and drug safety · 2018Observational
- Kidney Disease in HIV: Moving beyond HIV-Associated Nephropathy.Journal of the American Society of Nephrology : JASN · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
objectiveAtazanavir (ATV) and lopinavir (LPV) have been associated with kidney disease progression in HIV positive patients, with no data reported for darunavir (DRV). We examined kidney function in patients who switched their protease inhibitor from ATV or LPV to DRV.
designCohort study.
methodsData were from the UK CHIC study. We compared pre and post switch estimated glomerular filtration rate (eGFR) slopes (expressed in ml/min per 1.73 m per year) in all switchers and those with rapid eGFR decline (>5 ml/min per 1.73 m per year) on ATV or LPV. Mixed-effects models were adjusted for age, gender, ethnicity, eGFR at switch and time updated CD4 cell count, HIV RNA and cumulative tenofovir (tenofovir disoproxil fumarate) exposure.
resultsData from 1430 patients were included. At the time of switching to DRV, median age was 45 years, 79% were men, 76% had an undetectable viral load, and median eGFR was 93 ml/min per 1.73 m. Adjusted mean (95% confidence interval) pre and post switch eGFR slopes were -0.84 (-1.31, -0.36) and 1.23 (0.80, 1.66) for ATV (P < 0.001), and -0.57 (-1.09, -0.05) and 0.62 (0.28, 0.96) for LPV (P < 0.001). Stable or improved renal function was observed in patients with rapid eGFR decline on ATV or LPV who switched to DRV [-15.27 (-19.35, -11.19) and 3.72 (1.78, 5.66), P < 0.001 for ATV, -11.93 (-14.60, -9.26) and 0.87 (-0.54, 2.27), P < 0.001 for LPV]. Similar results were obtained if participants who discontinued tenofovir disoproxil fumarate at the time of switch were excluded.
conclusionsWe report improved kidney function in patients who switched from ATV or LPV to DRV, suggesting that DRV may have a more favourable renal safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.